Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.180
+0.150 (14.56%)
At close: Jun 9, 2025, 4:00 PM
1.210
+0.030 (2.54%)
After-hours: Jun 9, 2025, 6:50 PM EDT
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $66.62 million as of June 9, 2025. Its market cap has decreased by -70.56% in one year.
Market Cap
66.62M
Enterprise Value
-14.53M
1-Year Change
-70.56%
Ranking
Category
Stock Price
$1.18
Market Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $66.62M, a decrease of -91.74%. That is a compound annual growth rate of -41.13%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 9, 2025 | 66.62M | -5.05% |
| Dec 31, 2024 | 70.17M | -73.80% |
| Dec 29, 2023 | 267.79M | -6.83% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | 3.03B | 276.02% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 693.72B |
| Johnson & Johnson | 374.31B |
| AbbVie | 335.90B |
| Novo Nordisk | 332.47B |
| UnitedHealth Group | 273.87B |
| Abbott Laboratories | 231.78B |
| Novartis AG | 231.17B |
| AstraZeneca | 226.14B |